NUTRA PHARMA CORP

Form 4

March 21, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Check this box

if no longer

Section 16.

Form 4 or

subject to

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

DEITSCH RIK J

NUTRA PHARMA CORP [NPHC]

(Check all applicable)

(Last)

(First)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

12502 WEST ATLANTIC AVENUE 10/18/2012

Symbol

_X__ 10% Owner _X__ Director X_ Officer (give title _ Other (specify

below)

President, CEO

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

CORAL SPRINGS, FL 33065

(City)	(State)	(Zip)	Table I - N	on-Derivative S	ecurit	ies Acquire	ed, Disposed of, o	r Beneficially	Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transacti Code (Instr. 8)	r. 8) (A)			5. Amount of 6. Securities Owners! Beneficially Form: Owned Direct (I Following or Indirect (I) Transaction(s) (Instr. 4		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)		
Nutra Pharma Corp	10/18/2012		A	7,500,000	A	\$ 0.022	69,718,334	D	
Nutra Pharma Corp	12/10/2012		P	200,000	A	\$ 0.0149	69,918,334	D	
Nutra Pharma Corp	12/19/2012		P	10,000,000	A	\$ 0.01	79,918,334	D	
Nutra Pharma	06/27/2013		P	25,000,000	A	\$ 0.004	104,918,334	D	

Corp

Nutra					\$		
	09/09/2013	P	25,000,000	A	0.0025	129,918,334	D
Corp							
~ ~							

Nutra

Pharma 11/25/2013 A 11,760,000 A \$ 0.014 141,678,334 D

Corp

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (Instr.	ectio	5. nNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)
				Code	V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Deletionships

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
DEITSCH RIK J 12502 WEST ATLANTIC AVENUE CORAL SPRINGS, FL 33065	X	X	President, CEO				

Signatures

/s/ Rik J. Deitsch	03/20/2014	
**Signature of Reporting Person	Date	

Reporting Owners 2

Edgar Filing: NUTRA PHARMA CORP - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.